Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Comparing high-resolution and pQCT scans to view bone and muscle structure

Official title: Comparison of Bone Microarchitecture Analysed by High Resolution Peripheral Microscanner (HR-pQCT) and Peripheral Microscanner (pQCT) in Pathologies With Bone Loss and/or Muscle Loss

Run by Centre Hospitalier Universitaire de Saint Etienne · NCT06541548 · Data updated 2026-11-12

This study will try high-resolution CT (HR-pQCT), pQCT, and DXA scans to see if they reveal bone and muscle microarchitecture changes in adults at risk of osteoporosis or muscle loss.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1000 (estimated)
SponsorCentre Hospitalier Universitaire de Saint Etienne
Academic / other
Locations1 site (Saint-Etienne)
StatusRecruiting
StartedFebruary 2, 2026
Main results expectedMay 2035
Study endsMay 2035
Registry record updatedMarch 3, 2026
Trial IDNCT06541548 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults treated at CHU Saint-Etienne with osteoporosis risk or bone fragility and associated conditions listed in the protocol (inflammatory joint disease, chronic kidney disease, specified endocrinopathies, sarcopenia, obesity, anorexia, constitutional thinness, or Parkinson's disease) as well as eligible control participants with recent acute spinal/radicular pain meeting the control criteria.

Probably not a fit

Patients who do not consent, who are taking long-term medications known to induce bone loss (where exclusions apply), or who cannot undergo the imaging procedures are unlikely to receive benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Participants with osteoporosis risk or related conditions (for example rheumatoid arthritis, spondyloarthritis, chronic kidney disease, endocrinopathies, sarcopenia, obesity, anorexia, constitutional thinness, or Parkinson's disease) and a control group will undergo imaging with HR-pQCT (XtremeCT), pQCT (XCT 3000) and DXA. The study compares cortical porosity, trabecular volume and other microarchitectural measures between pathological groups and age-matched controls to distinguish disease-related changes from normal aging. Imaging data will be collected at a single center (CHU Saint-Etienne) and analyzed to characterize differences across conditions. Results aim to clarify which imaging modality best detects microstructural changes that relate to bone fragility.

Why it matters

Potential benefit: If successful, the study could improve identification of patients at higher fracture risk and guide more targeted prevention or treatment.

How similar studies have gone: Previous research has shown HR-pQCT can reveal microarchitectural bone changes that DXA misses, but head-to-head comparisons across the wide set of pathologies included here remain relatively limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

For the patients:

Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies:

* Osteoporosis defined by: History of a documented brittle bone fracture
* Bone fragility: Patient with indication for bone densitometry but no history of fracture
* Inflammatory joint disease:

  * Rheumatoid arthritis
  * Spondyloarthritis
* Chronic kidney disease
* Endocrinopathies:

  * Primary hyperparathyroidism
  * Constitutional thinness
  * Anorexia nervosa
  * Obesity (BMI \>30)
  * Sarcopenia
* Neuropathies - Parkinson's disease

For the controls:

Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent

Exclusion Criteria:

* No sign written consent

For the controls:

* Medications inducing bone loss:
* anti-aromasin or GnRH agonist for at least 6 months,
* corticosteroids (dose ≥ 5 mg/d for 6 months)
* anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)
* History of fracture due to bone fragility
* Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)

Where it's running

  • Chu Saint Etienne
    Saint-Etienne, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.